A detailed history of Quantum Private Wealth, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Quantum Private Wealth, LLC holds 767,616 shares of TSHA stock, worth $1.4 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
767,616
Previous 730,520 5.08%
Holding current value
$1.4 Million
Previous $1.64 Million 5.75%
% of portfolio
0.54%
Previous 0.6%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$2.01 - $2.46 $74,562 - $91,256
37,096 Added 5.08%
767,616 $1.54 Million
Q2 2024

Jul 17, 2024

BUY
$2.04 - $4.17 $65,280 - $133,440
32,000 Added 4.58%
730,520 $1.64 Million
Q1 2024

May 07, 2024

BUY
$1.43 - $3.25 $84,370 - $191,750
59,000 Added 9.23%
698,520 $2 Million
Q4 2023

Jan 30, 2024

BUY
$1.33 - $2.88 $85,306 - $184,723
64,140 Added 11.15%
639,520 $1.13 Million
Q3 2023

Nov 02, 2023

BUY
$0.63 - $3.66 $44,730 - $259,860
71,000 Added 14.08%
575,380 $1.82 Million
Q2 2023

Jul 27, 2023

BUY
$0.59 - $0.87 $85,557 - $126,161
145,013 Added 40.35%
504,380 $332,000
Q1 2023

Apr 19, 2023

BUY
$0.65 - $2.3 $29,841 - $105,592
45,910 Added 14.65%
359,367 $287,000
Q4 2022

Jan 20, 2023

BUY
$1.39 - $2.98 $117,299 - $251,476
84,388 Added 36.84%
313,457 $0
Q3 2022

Nov 01, 2022

BUY
$1.76 - $4.94 $125,479 - $352,197
71,295 Added 45.19%
229,069 $442,000
Q2 2022

Aug 17, 2022

BUY
$2.47 - $6.77 $14,326 - $39,266
5,800 Added 3.82%
157,774 $586,000
Q1 2022

May 27, 2022

BUY
$5.22 - $11.86 $32,656 - $74,196
6,256 Added 4.29%
151,974 $990,000
Q4 2021

May 26, 2022

BUY
$11.43 - $19.2 $1.67 Million - $2.8 Million
145,718 New
145,718 $1.7 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $88.5M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Quantum Private Wealth, LLC Portfolio

Follow Quantum Private Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantum Private Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quantum Private Wealth, LLC with notifications on news.